Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising burden of liver cancer
3.2.1.2 Increasing R&D investments for the development of novel therapies
3.2.1.3 Rising aging population
3.2.1.4 Government initiatives to increase cancer awareness
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with certain medications
3.2.2.2 High cost of cancer therapies
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Future market trends
3.7 Porters analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Hepatocellular carcinoma
5.3 Cholangiocarcinoma
5.4 Hepatoblastoma
5.5 Liver metastasis
5.6 Other types
Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Chemotherapeutic agents
6.3 Targeted therapy drugs
6.4 Immunotherapy drugs
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Injectable
Chapter 8 Market Estimates and Forecast, By Medication Type, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Generic
8.3 Branded
Chapter 9 Market Estimates and Forecast, By Gender, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Male
9.3 Female
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 Saudi Arabia
10.6.2 South Africa
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AbbVie Inc.
11.2 Amgen Inc.
11.3 AstraZeneca Plc
11.4 Bayer AG
11.5 Bristol-Myers Squibb Company
11.6 Eisai Co., Ltd.
11.7 Exelixis, Inc.
11.8 F. Hoffmann-La Roche Ltd.
11.9 Johnson & Johnson
11.10 Merck & Co., Inc.
11.11 Novartis AG
11.12 Sanofi SA
11.13 Thermo Fisher Scientific Inc.
